Intrinsic LifeSciences is a pioneer in the discovery, development, and distribution of the world’s first hepcidin ELISA (enzyme-linked immunosorbent assay), the key hormone regulating iron homeostasis in humans. Research teams lead by the founders independently discovered hepcidin in human urine and fish and went on to perform pioneering studies that helped define the regulation of hepcidin synthesis in the liver, its mechanism of action in iron homeostasis, and hepcidin’s role in disease and infection. In a seminal publication in Blood, the ILS team described the first ELISA for measurement of hepcidin in serum and urine, defined the normal serum ranges for hepcidin in adult women and men, and its levels in adults and children suffering from a number of debilitating diseases. ILS is focused on development of the first FDA-approved blood test for hepcidin and continues to expand their portfolio of related diagnostic products to facilitate research, diagnosis, and monitoring and treatment of prevalent iron disorders.

Our vision is to be the world’s leading provider of innovative in vitro diagnostics from anemia, iron overload diseases, and metabolic inflammatory diseases.